Abbott announced that its Assert-IQ™ insertable cardiac monitor (ICM) has received U.S. FDA clearance, giving physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing irregular heartbeats.
The Assert-IQ ICM is a significant advancement amongst the tools that are currently available for the diagnoses of irregular heart rhythms. The device is small and is inserted just under the skin, patients can go about their daily lives, enjoying the activities, and the ICM does the work.
With Assert-IQ ICM’s advanced algorithms, it can detect even hard-to-spot irregularities and help physicians determine a treatment course. It can be a very valuable tool both for short-term and long-term management of cardiac arrhythmia disorders.
The Assert-IQ ICM also offers advanced diagnostic capabilities to provide physicians with more clinically relevant information about the cardiovascular health of the patient, allowing care providers to make clinical decisions faster. Using Bluetooth® technology, Assert-IQ ICM is designed to remain connected to a transmitter – usually the person’s own cell phone – where it cheques heart rhythms every 20 seconds, transmitting results in real-time to the clinic’s portal.
